NEULANDLAB Neuland Laboratories Q4 FY26 results (Jan–Mar 2026) and concall
Neuland Labs delivered a robust Q4 and FY26 performance, with Q4 revenue surging 134.9% YoY to INR 788.7 crores and full-year revenue growing 37.1% to INR 2053.1 crores, accompanied by significant EBITDA margin expansion. Despite strong top-line growth, FY26 free cash flow was negative INR 49.4 crores due to increased working capital and capital expenditures. The company is strategically investing in peptide capabilities and R&D, while managing inherent business volatility and geopolitical risks.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 136.6%, net profit up 660.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 311 | 398 | 328 | 293 | 514 +65% | 440 +11% | 776 +137% |
| EBITDA | 61 | 86 | 51 | 34 | 155 +154% | 77 −10% | 307 +502% |
| Net profit | 32 | 101 | 28 | 14 | 96 +200% | 40 −60% | 213 +661% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
